Search

Displaying results 4641 - 4650 of 8010 in total
  1. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    XenoPort in 2011 for the treatment of GERD. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  2. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels. … It was investigated as a potential treatment for various pain conditions.

  3. Drug

    Sulfinpyrazone

    go.drugbank.com/drugs/DB01138
    Approved

    A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.

  4. Drug

    Oxabolone cipionate

    go.drugbank.com/drugs/DB13185
    Experimental

    It is considered as a performance enhancing drug thus is prohibited from use in sports.

    Categories: Anabolic Agents for Systemic Use
  5. Drug

    Monensin

    go.drugbank.com/drugs/DB11430
    ExperimentalVet approved

    Monensin is a polyether isolated from _Streptomyces cinnamonensis_ that presents antibiotic properties. It is widely used in ruminant animal feeds.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. … The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.

  7. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. … Arbaclofen was investigated as a treatment for gastroesophageal reflux disease (GERD); however, with disappointing results.

  9. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). … made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand for

  10. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.